Nanotherapeutics Overview

Principles

Definition

Nanotherapeutics is a research field and academic concept focused on the application of nanotechnology for diagnostic, therapeutic, and preventive medical interventions. It investigates the design, synthesis, and utilization of nanoscale materials and devices to achieve targeted drug delivery, enhance therapeutic efficacy, reduce toxicity, and enable novel treatment modalities for various diseases.

Ontological type

Core Platforms

Clinical Applications

Targeting Strategies

Key developments

Key Figures

Targeted Systemic Delivery era

In the Targeted Systemic Delivery era (2002–2010), representative authors such as Omid Farokhzad and Robert Langer advanced receptor-specific, surface-functionalized polymeric nanoparticles capable of delivering nucleic acids, chemotherapeutics, and antimicrobials systemically with controlled release. Their work demonstrated receptor-targeted uptake through ligands and antibodies and emphasized carrier architectures optimized for intravenous stability and tunable pharmacokinetics. Rakesh K. Jain contributed critical insights into tumor vasculature and the Enhanced Permeability and Retention effect, guiding nanoparticle design toward improved systemic delivery, safety assessments, and translational potential. Imaging-enabled nanomedicine, exemplified by Ralph Weissleder and colleagues, integrated diagnostic signals with therapeutic nanoparticles to monitor biodistribution and payload release, supporting early clinical evaluation.

Photothermal Nanomedicine era

Hongjie Dai [1] is a prominent researcher affiliated with Stanford University [2] and the South China University of Technology [3]. His 2011 work Ultrasmall Reduced Graphene Oxide with High Near-Infrared Absorbance for Photothermal Therapy [4] demonstrated ultrasmall graphene oxide with strong NIR absorption to drive photothermal therapy, a critical advance for nanoscale cancer therapies and the integration of imaging-guided theranostics in this era.

Biomimetic Nanoimmunotherapy era

Omid Farokhzad (Harvard/BWH) helped propel nanotherapeutics into the biomimetic realm by developing cell-membrane cloaks and other biomimetic nanoparticle strategies to evade immune clearance and enhance tumor targeting for immunomodulation. Dan Peer (Tel Aviv University) advanced programmable lipid nanoparticle platforms that deliver immune modulators and support in situ immune activation within the tumor microenvironment. Robert Langer (MIT) and colleagues laid essential translational groundwork for scalable nanoplatforms and lipid nanoparticle formulations that can carry immunotherapies toward clinical translation. Drew Weissman (UCSF) and collaborators advanced mRNA-LNP technologies that enable robust in vivo immune programming and underpin immunotherapy strategies emblematic of the biomimetic nanoimmunotherapy era (2018–2024).